Patient Enrollment. Any patient enrollment projections are good faith estimates and PPD shall exercise commercially reasonable efforts to meet such enrollment projections.
Patient Enrollment. The parties agree that enrollment numbers are good faith estimates and that various factors outside of PPD’s control can affect the rate of enrollment. PPD shall exercise all reasonable efforts to meet such enrollment estimates, but cannot guarantee that enrollment numbers or enrollment timelines will be met, provided however that the Sponsor shall not be responsible for delays in enrollment timelines as a result of PPD’s negligence or willful misconduct.
Patient Enrollment. For the avoidance of doubt, the parties understand and agree that enrollment rates set forth in connection with a Project are good faith estimates only and PPD shall exercise all reasonable diligence to meet enrollment expectations.
Patient Enrollment. Customer shall use commercially reasonable efforts to persuade Eligible Patients to consent to receive CCM Services and to actually accept CCM Services each month from a Case Manager.
Patient Enrollment. Receipt of the initial applications with respect to each of the Programs, and application review, general program eligibility determination and enrollment functions with respect to each Program, shall be the responsibility of the applicable Nominated Agent.
Patient Enrollment. The Study is competitive for patient recruitment. Approximately 250 sites will be recruiting worldwide for a total of 1200 randomized patients. The Sponsor anticipates that the Site will randomize approximately 5 subjects, but makes no guarantees regarding this number. PRA or the Sponsor will advise on recruitment progress and notify the Site when recruitment is complete.The milestone payments represent fair market value for the performance of the research services detailed in the Time and Events Schedule of the Protocol dated May 08, 2013 provided herein by reference in Exhibit B.The parties agree that in the event subsequent protocol amendments result in a material change to the research services required, the compensation will be adjusted accordingly to represent any such change to the fair market value through a written amendment signed by all parties hereto.
Patient Enrollment. Borrower Representative shall have provided Lenders with evidence reasonably satisfactory to Lenders that, on or before the Loan C Commitment Termination Date, not less than four hundred (400) patients have been enrolled in Part A of Co-Borrowers’ Phase III clinical trial for Borrower’s TTP488 drug. Lenders acknowledge that Co-Borrowers have, as of the date of this Agreement, satisfied the requirement set forth in this subsection (c).
Patient Enrollment. Enrollment numbers are good faith estimates and PPD shall exercise reasonable diligence and efforts to meet such enrollment estimates in accordance with any mutually agreed upon estimated time-lines.
Patient Enrollment. Acuity has enrolled not less than ten (10) human patients in a Phase II clinical trial of its “Cand5” drug for the treatment of age related macular degeneration, which trial has been approved by the FDA to be conducted in the United States.
Patient Enrollment. Enrollment numbers are good faith estimates and Service Provider shall exercise all reasonable diligence to meet such enrollment estimates.
